<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="253">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05233774</url>
  </required_header>
  <id_info>
    <org_study_id>00-007-01</org_study_id>
    <nct_id>NCT05233774</nct_id>
  </id_info>
  <brief_title>Lomecel-B Effects on Alzheimer's Disease</brief_title>
  <acronym>CLEARMIND</acronym>
  <official_title>Lomecel-B Effects on Alzheimer's Disease: A Randomized, Double-Blinded, Placebo-Controlled Phase 2a Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Longeveron Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>bioRASI, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Longeveron Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dementia resulting from AD is associated with vascular function decline and involves a&#xD;
      pro-inflammatory state. In our Phase 1 trial, Lomecel-B treatment met the primary safety&#xD;
      endpoint, with no safety concerns, and showed potential to improve clinical assessments.&#xD;
      Mechanistically, Lomecel-B treated subjects had higher serum concentrations of pro-vascular&#xD;
      and anti-inflammatory biomarkers relative to placebo. This trial builds upon those&#xD;
      preliminary Phase 1 results, and is designed to evaluate the safety profile of multiple&#xD;
      infusions of Lomecel-B, and to investigate provisional efficacy of single dosing versus&#xD;
      multiple dosing of Lomecel-B on cognitive function and biomarkers in AD subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 28, 2021</start_date>
  <completion_date type="Anticipated">September 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 29, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study consists of 4 study arms of 12 patients each.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoint 1: Safety - SAEs and AEs</measure>
    <time_frame>41 weeks</time_frame>
    <description>To demonstrate that Lomecel-B infusions do not trigger the pre-specified stopping rules.&#xD;
Additional safety will be acquired throughout the study as follows: Incidence of all AEs and SAEs over the course of the trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Endpoint 2: Safety - Imaging</measure>
    <time_frame>41 weeks</time_frame>
    <description>To demonstrate that Lomecel-B infusions do not trigger the pre-specified stopping rules.&#xD;
Additional safety will be acquired throughout the study as follows: Alzheimer's disease-related imaging abnormalities (ARIA) or clinically asymptomatic microhemorrhages as revealed by MRI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint 2: Efficacy- Change in the ADAS-cog-13</measure>
    <time_frame>41 weeks</time_frame>
    <description>Change from baseline in the ADAS-cog-13 in Lomecel-B-treated arms versus change in placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint 3: Efficacy- Change in the MMSE</measure>
    <time_frame>41 weeks</time_frame>
    <description>Change from baseline in the MMSE in Lomecel-B-treated arms versus change in placebo.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Mild Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 1 will receive four infusions of Placebo on Day 0, Week 4, Week 8, and Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lomecel-B Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 will receive an infusion of Lomecel-B at a dose of 25 x 10^6 cells (25M) on Day 0, followed by Placebo infusions at Week 4, Week 8, and Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lomecel-B Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3 will receive four infusions of 25M Lomecel-B on Day 0, Week 4, Week 8, and Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lomecel-B Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 4 will receive four infusions of Lomecel-B at a dose of 100 x 10^6 cells (100M) on Day 0, Week 4, Week 8, and Week 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allogeneic MSC</intervention_name>
    <description>An allogeneic bone marrow-derived medicinal signaling cell (MSC) formulation</description>
    <arm_group_label>Lomecel-B Dose 1</arm_group_label>
    <arm_group_label>Lomecel-B Dose 2</arm_group_label>
    <arm_group_label>Lomecel-B Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide written informed consent.&#xD;
&#xD;
          -  Be 60 - 85 years of age at signing of the Informed Consent Form.&#xD;
&#xD;
          -  Clinical diagnosis of mild Alzheimer's disease in accordance with the NIA-AA criteria&#xD;
             at the time of enrollment.&#xD;
&#xD;
          -  MMSE score of 19 - 23.&#xD;
&#xD;
          -  Body weight of 40 - 150 kg.&#xD;
&#xD;
          -  Has an adult caregiver who meets all of the following criteria.&#xD;
&#xD;
               1. Provides written informed consent to participate on the trial (reporting on&#xD;
                  patient observations).&#xD;
&#xD;
               2. Either lives with the patient, or sees the patient for at least 2 hours/day for&#xD;
                  at least 3 days/week.&#xD;
&#xD;
               3. Is willing and able to participate in the study, and agrees to accompany the&#xD;
                  patient to each study visit.&#xD;
&#xD;
               4. Is able to read, understand, and speak the designated language at the study site.&#xD;
&#xD;
          -  Brain MRI consistent with AD.&#xD;
&#xD;
          -  A PET scan using an FDA-approved tracer (e.g., AMYViD, Vizamyl, or Neuraceq)&#xD;
             consistent with the diagnosis of AD. A prior positive PET scan will be allowed with&#xD;
             Sponsor approval.&#xD;
&#xD;
          -  Living in the community, includes assisted living facilities (but excluding long-term&#xD;
             care nursing facilities).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with frontotemporal dementia (FTD), dementia due to Acquired&#xD;
             Immunodeficiency Syndrome (AIDS), Creutzfeldt-Jakob disease (CJD), Lewy Bodies&#xD;
             dementia (LBD), Progressive Supranuclear Palsy (PSP), multiple cerebral infarctions,&#xD;
             or normal pressure hydrocephalus.&#xD;
&#xD;
          -  Any other neurodegenerative disease.&#xD;
&#xD;
          -  History of a seizure disorder.&#xD;
&#xD;
          -  Evidence of: a prior macrohemorrhage; at least 4 cerebral microhemorrhages (regardless&#xD;
             of anatomical location or diagnostic characterization as &quot;possible&quot; or &quot;definite&quot;); or&#xD;
             at least 1 area of superficial siderosis.&#xD;
&#xD;
          -  Unwillingness or inability to have MRIs scans (no contrasting agent will be used), or&#xD;
             condition that contraindicates MRI, such as the presence metallic objects in the eyes,&#xD;
             skin, or heart.&#xD;
&#xD;
          -  Any conditions that contraindicates PET with a beta-amyloid tracer.&#xD;
&#xD;
          -  Significant intestinal malabsorption surgery, e.g., gastric bypass.&#xD;
&#xD;
          -  Serum B12 and/or folate levels below normal range.&#xD;
&#xD;
          -  Clinically abnormal free T4 or thyroid-stimulating hormone (TSH).&#xD;
&#xD;
          -  Resting blood oxygen saturation &lt;93%.&#xD;
&#xD;
          -  Resting systolic blood pressure &gt;180 mm Hg, or diastolic blood pressure &gt;110 mm Hg.&#xD;
&#xD;
          -  Regularly (&gt; 4 weeks) using high-doses of corticosteroids or other steroidal&#xD;
             anti-inflammatory medication (e.g., Prednisone) on a regular basis, with the exception&#xD;
             of steroidal nasal sprays, asthma inhalers, topical steroids, and hormonal-replacement&#xD;
             therapy.&#xD;
&#xD;
          -  Regularly (&gt; 4 weeks) using anti-cytokine antibody or targeting therapy, e.g.,&#xD;
             anti-TNF-Î±.&#xD;
&#xD;
          -  Be an organ transplant recipient, or have active or expected future listing for any&#xD;
             organ/tissue transplant while scheduled to be on trial, except for corneal, bone,&#xD;
             skin, ligament, or tendon.&#xD;
&#xD;
          -  Diagnosed with malignancy within the past 2 years, with the exception of curatively&#xD;
             treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ, or cervical&#xD;
             carcinoma.&#xD;
&#xD;
          -  Known hypersensitivity to dimethyl sulfoxide (DMSO).&#xD;
&#xD;
          -  Test positive for hepatitis B virus surface antigen, viremic hepatitis C virus, HIV,&#xD;
             or syphilis.&#xD;
&#xD;
          -  Any condition that is projected to limited life expectancy to &lt; 12 months.&#xD;
&#xD;
          -  Be pregnant, nursing, or of childbearing potential while not practicing effective&#xD;
             contraception.&#xD;
&#xD;
          -  Be currently participating in any other investigational therapeutic or device trial,&#xD;
             or have participated within one within the previous 30 days to screening, or in the&#xD;
             opinion of the investigator, the patient should be excluded for such participation&#xD;
             within the past 5 years.&#xD;
&#xD;
          -  In the opinion of the investigator, the patient has any other illness or condition&#xD;
             that: may compromise the participant's safety, compliance, or ability to successfully&#xD;
             complete the study; may compromise the validity of the study; or otherwise should&#xD;
             exclude the participant from enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kevin N Ramdas, MD, MPH</last_name>
    <phone>(786) 543-6793</phone>
    <email>ALZresearch@longeveron.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nana Yakoubov</last_name>
    <email>Regulatory_Affairs@biorasi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Visionary Investigators Network</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wisline Fenelus</last_name>
      <phone>305-336-5713</phone>
      <email>wfenelus@vintrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda Gonzalez</last_name>
      <phone>561-374-8461</phone>
      <phone_ext>1141</phone_ext>
      <email>ygonzalez@ergclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Science Connections - Research Partner Group Multispecialty Group</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33178</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Oliver</last_name>
      <phone>786-521-8103</phone>
      <email>molivera@scienceconnections.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bruce W. Carter VA Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victor Cevallos</last_name>
      <phone>305-575-7000</phone>
      <phone_ext>16993</phone_ext>
      <email>Victor.Cevallos2@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami Jewish Health</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Rodriguez</last_name>
      <phone>305-751-8626</phone>
      <phone_ext>64104</phone_ext>
      <email>jrodriguez4@miamijewishhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allied Biomedical Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis Estevez</last_name>
      <phone>305-643-8400</phone>
      <email>lestevez@abriusa.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ivetmar Medical Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Cabrera</last_name>
      <phone>754-800-9075</phone>
      <email>andrea.cabrera@ivetmar.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fusion Medical Research and Clinic</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Ocana</last_name>
      <phone>305-609-6464</phone>
      <email>melissaocana@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Excellent Research Group, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milka Vina</last_name>
      <phone>786-285-5631</phone>
      <email>mvina@firstexcellentresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brainstorm Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Savannah Rodriguez</last_name>
      <phone>305-596-2080</phone>
      <phone_ext>1112</phone_ext>
      <email>srodriguez@brainstormresearch.net</email>
    </contact>
    <contact_backup>
      <last_name>David Rasch</last_name>
      <phone>305-596-2080</phone>
      <phone_ext>1111</phone_ext>
      <email>drasch@brainstormresearch.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Miami Dade Medical Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stacy Machado</last_name>
      <phone>305-722-7210</phone>
      <email>smachado@miamimedresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imic Inc.</name>
      <address>
        <city>Palmetto Bay</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolas Boris</last_name>
      <phone>305-338-0568</phone>
      <email>boris@aktamedika.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34997</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Kirk</last_name>
      <phone>772-223-7809</phone>
      <email>PKirk@ergclinical.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2022</verification_date>
  <study_first_submitted>December 16, 2021</study_first_submitted>
  <study_first_submitted_qc>January 31, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2022</study_first_posted>
  <last_update_submitted>August 15, 2022</last_update_submitted>
  <last_update_submitted_qc>August 15, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

